2. Academic Validation
  3. KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes

KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes

  • Chem Biol. 2015 Sep 17;22(9):1185-96. doi: 10.1016/j.chembiol.2015.08.007.
Lingling Duan 1,  Ganesha Rai 2,  Carlos Roggero 3,  Qing-Jun Zhang 1,  Qun Wei 1,  Shi Hong Ma 4,  Yunyun Zhou 5,  John Santoyo 4,  Elisabeth D Martinez 6,  Guanghua Xiao 5,  Ganesh V Raj 4,  Ajit Jadhav 2,  Anton Simeonov 2,  David J Maloney 2,  Josep Rizo 3,  Jer-Tsong Hsieh 4,  Zhi-Ping Liu 7
Affiliations

Affiliations

  • 1 Departments of Internal Medicine and Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
  • 2 National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, MD 20850, USA.
  • 3 Department of Biophysics, UT Southwestern Medical Center, Dallas, TX 75390, USA; Department of Biochemistry and Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
  • 4 Department of Urology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
  • 5 Department of Clinical Science, UT Southwestern Medical Center, Dallas, TX 75390, USA.
  • 6 Department of pharmacology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
  • 7 Departments of Internal Medicine and Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: zhi-ping.liu@utsouthwestern.edu.
PMID: 26364928 DOI: 10.1016/j.chembiol.2015.08.007
Abstract

Histone lysine demethylase KDM4/JMJD2s are overexpressed in many human tumors including prostate Cancer (PCa). KDM4s are co-activators of Androgen Receptor (AR) and are thus potential therapeutic targets. Yet to date few KDM4 inhibitors that have anti-prostate tumor activity in vivo have been developed. Here, we report the anti-tumor growth effect and molecular mechanisms of three novel KDM4 inhibitors (A1, I9, and B3). These inhibitors repressed the transcription of both AR and BMYB-regulated genes. Compound B3 is highly selective for a variety of Cancer cell lines including PC3 cells that lack AR. B3 inhibited the in vivo growth of tumors derived from PC3 cells and ex vivo human PCa explants. We identified a novel mechanism by which KDM4B activates the transcription of Polo-like kinase 1 (PLK1). B3 blocked the binding of KDM4B to the PLK1 promoter. Our studies suggest a potential mechanism-based therapeutic strategy for PCa and tumors with elevated KDM4B/PLK1 expression.

Figures
Products